23andMe still aims to pivot to biotech despite plummeting valuation

Some of 23andMe's business moves led to financial problems, as the company still hopes for a future in pharmaceutical development.

Related Keywords

San Francisco ,California ,United States ,Americans ,Adam Neumann ,Larry Page ,Kimberly White Getty ,Marcus Wallenberg ,Sergey Brin ,Anne Wojcicki ,Rolfe Winkler ,Susan Wojcicki ,Lily Jamali ,Janet Wojcicki ,Nasdaq ,Google ,University Of California ,Silicon Valley ,Wall Street ,Prince Daniel ,Getty Images ,